EDEN PRAIRIE, Minn., July 12, 2018 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS), today announces it has entered
into the German market by expanding a relationship with HSC-Medical, GmbH, a business solutions resource based in Germany.
HSC-Medical will serve as a fulfillment house and logistical support for CHF Solutions, while the company’s current
international sales team will provide direct sales support in Germany. This is the first entry for the company into the
German market.
“We continue to expand into the European market, as planned,” said John Erb, Chairman and CEO of CHF Solutions. “We believe
strongly that physicians across the globe will benefit from using the Aquadex FlexFlow system to manage fluid overload, and we are
gratified that we continue to find excellent partners to help us grow our international sales opportunities.”
About CHF Solutions
CHF Solutions, Inc. (NASDAQ:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for
Aquapheresis® therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of
patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of
patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a
healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's
mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical
technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly
owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.
Forward-Looking Statements
Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995, including without limitation, the statement regarding the benefits from using the Aquadex FlexFlow for physicians
across the globe. Forward-looking statements are predictions, projections and other statements about future events that are
based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause
actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those
risk associated with our ability to execute on our recently announced strategic realignment, the possibility that we may be unable
to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits
of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to
increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property
protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from
acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only
as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
CONTACTS:
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
-or-
Bret Shapiro
Managing Partner
CORE IR
516-222-2560
brets@coreir.com
www.coreir.com
MEDIA
Jules Abraham
JQA Partners, Inc.
917-885-7378
jabraham@jqapartners.com
